A cannabinoid therapeutics stock got a lift following the release of financial results Thursday. Here’s some small stocks making big moves on Thursday, August 30, 2018 (as of 4 pm EST):
Kalytera Therapeutics, Inc. (TSXV:KALY), a cannabinoid therapeutics stock, moved 18% higher to $0.10 on Thursday after announcing second-quarter net income of approximately US$5.9 million, compared with a net loss of about $1.9 million in the second quarter of 2017, which was attributable primarily to an increase of approximately $8.9 million in financial income in connection with convertible equity and debt instruments previously issued to investors.
As well, shares of Pioneering Technology Corp. (TSXV:PTE) sank 27% to $0.19 as the cooking fire prevention technology provider said its third-quarter revenue fell 67% to 844,706.
Kraken Robotics Inc. (TSXV:PNG), meanwhile, reported record second-quarter revenue of $3.7 million, up from $0.2 million during the same period last year. The Company added that it expects strong momentum in the second half of 2018 and 2019. Kraken Robotics stock moved up 25% to $0.425 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Kalytera Therapeutics, Inc. (TSXV:KALY), a cannabinoid therapeutics stock, moved 18% higher to $0.10 on Thursday after announcing second-quarter net income of approximately US$5.9 million, compared with a net loss of about $1.9 million in the second quarter of 2017, which was attributable primarily to an increase of approximately $8.9 million in financial income in connection with convertible equity and debt instruments previously issued to investors.
